Cargando…

A meta‐analysis of toxicities related to hydroxycarbamide dosing strategies

Due to fear of short‐term toxicities, there is nonconsensus of hydroxycarbamide dosing strategy (escalated vs fixed‐dosing methods), which contributes to its suboptimal use. We performed a meta‐analysis to summarize the incidence rates of toxicities associated with both dosing methods. Summarized in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathias, Joacy G., Nolan, Vikki G., Meadows‐Taylor, Meghan, Robinson, L. Ashley, Howell, Kristen E., Gurney, James G., Hankins, Jane S., Wang, Winfred C., Estepp, Jeremie H., Smeltzer, Matthew P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176148/ https://www.ncbi.nlm.nih.gov/pubmed/35847723 http://dx.doi.org/10.1002/jha2.7

Ejemplares similares

Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance
por: Mathias, Joacy G., et al.
Publicado: (2021)

Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program
por: Nottage, Kerri A., et al.
Publicado: (2013)

Prevalence of Vitamin D Deficiency in Sickle Cell Disease: A Systematic Review
por: Nolan, Vikki G., et al.
Publicado: (2015)

P1436: AGEING IMPACTS HYDROXYCARBAMIDE DOSING IN PATIENTS WITH SICKLE CELL DISEASE
por: Doss, Isabelle, et al.
Publicado: (2023)

Hydroxycarbamide‐related cutaneous ulcer complicated by osteomyelitis
por: England, James T., et al.
Publicado: (2021)

High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia
por: Lebensburger, Jeffrey D., et al.
Publicado: (2020)

Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
por: Mathur, Abhinav, et al.
Publicado: (2022)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Hydroxycarbamide: Worsening thrombocytopenia and unmasking of lymphopenia: case report
Publicado: (2021)

Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease
por: Wiles, NM, et al.
Publicado: (2009)

Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms
por: Contreras Castillo, Stephania, et al.
Publicado: (2021)

Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
por: Kumkhaek, Chutima, et al.
Publicado: (2008)

Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case
por: Malkan, Umit Yavuz, et al.
Publicado: (2015)

Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide
por: Gaitanis, Georgios, et al.
Publicado: (2018)

Hypersegmentation of Granulocytes and Monocytes in a Patient with Primary Myelofibrosis Treated with Hydroxycarbamide
por: Błocka-Gumowska, Monika, et al.
Publicado: (2019)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach
por: Alberts, Nicole M, et al.
Publicado: (2020)

Real-World Association Between mRNA Vaccination and Infection From the Omicron Strain of SARS-CoV-2: A Population-Level Analysis
por: Plaxco, Allison P., et al.
Publicado: (2022)

Association Between mRNA Vaccination and Infection From SARS-CoV-2 During the Delta and Omicron BA.1 Waves: A Population-Level Analysis
por: Plaxco, Allison P., et al.
Publicado: (2023)

Hydroxycarbamide overdose: Marrow suppression presenting as neutropenia following accidental overdose: case report
Publicado: (2020)

Gilteritinib/hydroxycarbamide/remdesivir: Neutropenia, lack of efficacy and off-label use: case report
Publicado: (2021)

Detrimental effects of sickle cell disease and hydroxycarbamide on ovarian reserve but uncertain impact on fertility
por: Joseph, Laure, et al.
Publicado: (2023)

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
por: Harrison, Claire N., et al.
Publicado: (2023)

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera
por: Brusson, Mégane, et al.
Publicado: (2018)

5612984 AUDIT OF TRUST COMPLIANCE WITH BSH GUIDELINES FOR UTILISATION OF HYDROXYCARBAMIDE IN PATIENTS WITH SICKLE CELL DISEASE
por: Barker, R., et al.
Publicado: (2023)

Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings
por: Inusa, Baba Psalm Duniya, et al.
Publicado: (2018)

The association of infant feeding patterns with food allergy symptoms and food allergy in early childhood
por: Mathias, Joacy G., et al.
Publicado: (2019)

VWF–ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion
por: Fogarty, Helen, et al.
Publicado: (2023)

Chloroquine/dalteparin sodium/hydroxycarbamide: Prolongation of the QTc interval secondary to off-label use and lack of efficacy: case report
Publicado: (2021)

A Microbiota-Dependent Response to Anticancer Treatment in an In Vitro Human Microbiota Model: A Pilot Study With Hydroxycarbamide and Daunorubicin
por: Hobson, Claire Amaris, et al.
Publicado: (2022)

P1419: A SINGLE CENTRE PERSPECTIVE ON PREGNANCY OUTCOMES AND SICKLE CELL COMPLICATIONS IN WOMEN ON HYDROXYCARBAMIDE PERI-CONCEPTION.
por: Gregori, Maria, et al.
Publicado: (2023)

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
por: Godfrey, Anna L., et al.
Publicado: (2018)

P123: A SYSTEMATIC REVIEW OF THE BARRIERS TO UPTAKE AND ADHERENCE TO HYDROXYCARBAMIDE FROM THE PERSPECTIVE OF CHILDREN AND ADULTS WITH SICKLE CELL DISEASE, PARENTS AND CLINICIANS.
por: Clark, C
Publicado: (2022)

Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA
por: Smeltzer, Matthew P, et al.
Publicado: (2021)

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)
por: Mesa, Ruben, et al.
Publicado: (2016)

Feasibility of identifying families for genetic studies of birth defects using the National Health Interview Survey
por: Wyszynski, Diego F, et al.
Publicado: (2004)

Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease
por: Pandey, Akancha, et al.
Publicado: (2023)

Using a holistic approach to assess the impact of engineered nanomaterials inducing toxicity in aquatic systems
por: He, Xiaojia, et al.
Publicado: (2014)

Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis
por: Smeltzer, Matthew P., et al.
Publicado: (2021)

How to calculate the dose of chemotherapy
por: Gurney, H
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_ortv169fhb66auedt7khjjpnna